Affiliation:
1. Professor, Department Of Pediatrics, Raja Rajeswari Medical College And Hospital Banglore
2. HOD And Professor, Department Of Pediatrics, Raja Rajeswari Medical College And Hospital Banglore
3. Junior Resident, Department Of Pediatrics, Raja Rajeswari Medical College And Hospital Banglore
Abstract
Background: Caffeine is the most commonly consumed pharmacologically active compound in the world. In the neonatal intensive care units
(NICU), it is one of the most commonly prescribed drugs to treat Apnea of prematurity. Caffeine, the most commonly used medication in Neonatal
Intensive Care Units, has calciuric and osteoclastogenic effects. Our st Aims And Objectives: udy aims to determine the association between
duration of therapy of caffeine and metabolic bone disease in less than 34 weeks of gestation . All preterm babies(< 34 weeks) Inclusion Criteria:
Exclusion Criteria: Methods: Neonates with major congenital anomalies and congenital bone diseases, babies >34 weeks. To determine the
association between the duration of therapy of caffeine and metabolic bone disease, a prospective observational study was conducted including
premature neonates less than 34 weeks . Metabolic Bone Disease was evaluated by using Biochemical parameters like calcium ,phosphorous
,ALP, calcium : creatinine ratio at 4 weeks of postnatal period . The Results: prospective observational study included 35 infants. 5.7 % had
metabolic bone disease. caffeine therapy showed a association with metabolic bone disease. The duration of therapy of caffeine Conclusion:
associated with metabolic bone disease and lesser the gestational age ,requirement of caffeine for longer duration in this group of study and .
Future studies are needed to conrm these ndings and determine the lowest dose of caffeine needed to treat effectively apnea of prematurity
Subject
General Medicine,Psychiatry and Mental health,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine,Family Practice,Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,General Medicine,General Medicine,Care Planning,Public Health, Environmental and Occupational Health,Animal Science and Zoology,Nature and Landscape Conservation,Animal Science and Zoology,Ecology, Evolution, Behavior and Systematics
Reference26 articles.
1. Vachharajani AJ, Mathur AM, Rao R. Metabolic bone disease of prematurity. NeoReviews. 2009;10(8):e402–11.
2. Heaney RP. Effects of caffeine on bone and the calcium economy. Food Chem Toxicol. 2002;40(9):1263–70.
3. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebocontrolled study. Pharmacotherapy. 2000;20(6):644–52.
4. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics. 2007; 119(5):936–40.
5. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev. 1999;51(1):83–133.